Medical specialists from France tagged as investigators in clinical trials studying Usher Syndrome

Total 19 results

Bahram Bodaghi
Seen in:
- Paris, CHU Pitié Salpétrière
Trials:
- NCT04665726 (Principal Investigator)
Conditions:
- Usher Syndromes
Christel Vaché, PhD
Seen in:
- Montpellier, CHU, Laboratoire de génétique moléculaire, INSERM
Trials:
- NCT01954953 (Principal Investigator)
Conditions:
- Usher Syndrome
Georges Challe
Seen in:
- Paris, CHU Pitié Salpétrière
Trials:
- NCT04665726 (Sub-Investigator)
Conditions:
- Usher Syndromes
Ieva Sliesoraityte, MD PhD
Seen in:
- Paris, CIC of CHNO des Quinze-vingts
Trials:
- NCT01954953 (Principal Investigator)
Conditions:
- Usher Syndrome
Isabelle Audo
Seen in:
- Paris, Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
Trials:
- NCT04665726 (Principal Investigator)
Conditions:
- Usher Syndromes
Isabelle Mosnier
Seen in:
- Paris, CHU Pitié Salpétrière
Trials:
- NCT04665726 (Principal Investigator)
Conditions:
- Usher Syndromes
Isabelle Rouillon
Seen in:
- Paris, CHU Necker
Trials:
- NCT04665726 (Sub-Investigator)
Conditions:
- Usher Syndromes
José Alain Sahel
Seen in:
- Paris, Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
Trials:
- NCT04665726 (Sub-Investigator)
Conditions:
- Usher Syndromes
Jose-Alain Sahel, MD PhD
Seen in:
- Paris, CIC of CHNO des Quinze-vingts
Trials:
- NCT01954953 (Principal Investigator)
Conditions:
- Usher Syndrome
Marine Parodi
Seen in:
- Paris, CHU Necker
Trials:
- NCT04665726 (Sub-Investigator)
Conditions:
- Usher Syndromes
Marion Blanchard
Seen in:
- Paris, CHU Necker
Trials:
- NCT04665726 (Sub-Investigator)
Conditions:
- Usher Syndromes
Michel Paques
Seen in:
- Paris, Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
Trials:
- NCT04665726 (Sub-Investigator)
Conditions:
- Usher Syndromes
Natalie Loundon
Seen in:
- Paris, CHU Necker
Trials:
- NCT04665726 (Principal Investigator)
Conditions:
- Usher Syndromes
Pascale Diehl Pradat
Seen in:
- Paris, CHU Pitié Salpétrière
Trials:
- NCT04665726 (Principal Investigator)
Conditions:
- Usher Syndromes
Raphaël Atia
Seen in:
- Paris, Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
Trials:
- NCT04665726 (Sub-Investigator)
Conditions:
- Usher Syndromes
Saddek Mohand-Said
Seen in:
- Paris, Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
Trials:
- NCT04665726 (Sub-Investigator)
Conditions:
- Usher Syndromes
Sandrine Marlin
Seen in:
- Paris, CHU Necker
Trials:
- NCT04665726 (Principal Investigator)
Conditions:
- Usher Syndromes
Sarah Mrejen
Seen in:
- Paris, Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
Trials:
- NCT04665726 (Sub-Investigator)
Conditions:
- Usher Syndromes
Sylvette Wiener Vacher
Seen in:
- Paris, CHU Robert Debré
Trials:
- NCT04665726 (Principal Investigator)
Conditions:
- Usher Syndromes

Clinical Trials on Usher Syndrome

Fondazione Telethon

Unknown

Natural History Study in Subjects With Usher Syndrome

Usher Syndrome, Type 1B

Italy, Netherlands, Spain
Neurotech Pharmaceuticals
University of California, San Francisco

Completed

Retinal Imaging in CNTF -Releasing Encapsulated Cell Implant Treated Patients for Early-stage Retinitis Pigmentosa

Retinitis Pigmentosa | Usher Syndrome Type 2 | Usher Syndrome Type 3

United States
Sanofi

Active, not recruiting

A Study to Determine the Long-Term Safety, Tolerability and Biological Activity of SAR421869 in Patients With Usher Syndrome Type 1B

Usher's Syndrome

United States, France
Sanofi

Terminated

Study of SAR421869 in Participants With Retinitis Pigmentosa Associated With Usher Syndrome Type 1B

Retinitis Pigmentosa | Usher Syndrome

United States, France
Radboud University Medical Center
Stichting Ushersyndroom

Active, not recruiting

Characterizing Rate of Progression in USHer Syndrome (CRUSH) Study (CRUSH)

Retinitis Pigmentosa | Usher Syndrome, Type 2A | USH2A

Netherlands
Jaeb Center for Health Research
Foundation Fighting Blindness

Active, not recruiting

Rate of Progression in USH2A-related Retinal Degeneration (RUSH2A)

Usher Syndrome, Type 2A | Retinitis Pigmentosa 39

United States, Canada, France, Germany, Netherlands, United Kingdom
ProQR Therapeutics

Terminated

An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa (HELIA)

Retinitis Pigmentosa | Usher Syndrome Type 2

United States, Canada, France
ProQR Therapeutics

Completed

Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Stellar)

Eye Diseases | Retinitis Pigmentosa | Eye Diseases, Hereditary | Vision Disorders | Retinal Disease | Eye Disorders Congenital | Usher Syndrome Type 2 | Deaf Blind

United States, Canada, France
ProQR Therapeutics

Active, not recruiting

Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius)

Eye Diseases | Retinitis Pigmentosa | Eye Diseases, Hereditary | Vision Disorders | Retinal Disease | Eye Disorders Congenital | Usher Syndrome Type 2 | Deaf Blind

United States, Netherlands, United Kingdom, Germany
ProQR Therapeutics

Terminated

Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste)

Eye Diseases | Retinitis Pigmentosa | Eye Diseases, Hereditary | Vision Disorders | Retinal Disease | Eye Disorders Congenital | Usher Syndrome Type 2 | Deaf Blind

United States, United Kingdom

Medical specialists from France tagged as investigators in clinical trials studying Usher Syndrome

Clinical Trials on Usher Syndrome

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lebanon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations